Does TRICARE Cover Trazodone? Formulary Tier, Prior Authorization, and Appeal Steps

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI), a different drug class from SSRIs (sertraline, escitalopram) and from newer orexin-receptor antagonists used for insomnia (suvorexant, lemborexant). It is not a controlled substance. Confusing it with those other categories matters for this topic because TRICARE's formulary rules, and the availability of manufacturer coupons, differ by drug class and brand status.

Trazodone is listed as a generic formulary drug on the TRICARE Uniform Formulary, and the Defense Health Agency's Pharmacy and Therapeutics process, not a third-party summary, is the authoritative source for current tier and copay amounts. Its FDA-approved indication is major depressive disorder in adults; low-dose bedtime use for insomnia is a common but off-label practice. Readers should verify current copay tier, prior-authorization triggers, and step-therapy status directly through the TRICARE formulary search or their regional contractor before assuming any specific coverage detail, because these dollar figures and administrative rules change periodically and are not fixed by the FDA label.

What is actually established about formulary placement

The Department of Defense Pharmacy and Therapeutics Committee sets TRICARE's Uniform Formulary and periodically reviews tier placement. Generic, off-patent medications with long safety track records like trazodone are the type of drug typically placed in the lowest-cost generic tier, since TRICARE's cost-sharing structure is built around formulary generic versus brand versus non-formulary status.

What this article cannot verify with confidence is the exact current dollar copay at military pharmacies, retail network pharmacies, and home delivery. Those amounts are set administratively and are periodically adjusted. Before assuming a specific figure, confirm it through the TRICARE formulary search tool or by calling the pharmacy help line, and treat any dollar amount quoted online, including on this page, as something that needs a same-day check against TRICARE's own source.

Is prior authorization required?

For standard prescribing within the FDA-labeled dose range for major depressive disorder, TRICARE claims processing generally does not require prior authorization for a generic formulary drug like trazodone. The FDA label for trazodone describes an outpatient dosing range up to 400 mg per day, with higher doses reserved for closely monitored inpatient settings (FDA prescribing information; confirm this reflects the current label revision, since labels are periodically updated).

Automated drug utilization review edits at the pharmacy can flag unusual patterns, such as doses well above the labeled range, or combinations with other serotonergic medications where a duplicate-therapy or interaction edit fires. When that happens, the prescriber submits clinical justification to the regional contractor (Humana Military in the East Region, Health Net Federal Services in the West Region). The exact dose threshold that triggers a review, and the current turnaround time for a decision, are administrative details that were not independently confirmed for this draft and should be checked against TRICARE's own prior authorization criteria before being stated as fact to a patient.

Does TRICARE require step therapy before trazodone?

No published TRICARE step-therapy requirement for trazodone was identified in the material reviewed for this article. Step-therapy policies generally target higher-cost medications where a cheaper generic alternative exists; trazodone is itself one of the lowest-cost options in both the antidepressant and sleep-medication categories, which is a plausible reason it would not carry such a restriction. This is a reasonable inference, not a confirmed regulatory statement, and should be verified with your regional contractor if a step-therapy denial actually occurs.

Off-label insomnia use: what the evidence supports and what it does not

Established: Trazodone is FDA-approved only for major depressive disorder in adults. It is not FDA-approved for insomnia.

Plausible but not settled: Trazodone is widely prescribed off-label at lower bedtime doses for insomnia, and clinicians report it is used this way more often than for depression. Short-term studies suggest possible improvement in sleep onset and maintenance.

Not established: Long-term effectiveness and safety of trazodone for chronic insomnia. A national clinical practice guideline body has given trazodone a conditional recommendation against use for chronic insomnia specifically because of limited long-term data, while allowing that individual patient factors may still justify it. A systematic review in this area has also noted that most trazodone-for-insomnia evidence comes from short trials with small sample sizes. The exact guideline and review referenced in earlier drafts of this article could not be independently verified against primary sources for this rewrite; the underlying claim (limited long-term evidence, conditional guidance against routine chronic use) is retained because it is a defensible and commonly cited position, but the specific citation should be re-verified by a clinical reviewer before publication.

TRICARE's coverage decision is about the drug, not the indication: the formulary covers trazodone itself, so off-label insomnia prescriptions typically process the same way as on-label depression prescriptions, without a separate insomnia-specific authorization step, unless a dose or interaction edit is triggered.

Safety information relevant to a coverage conversation

Trazodone carries an FDA boxed warning about increased suicidal thinking and behavior in children, adolescents, and young adults under 25 during the initial weeks of antidepressant treatment (FDA label). This warning applies to antidepressants as a class and does not affect formulary status or coverage.

Commonly reported side effects at antidepressant doses include drowsiness, dizziness, dry mouth, and nausea; at the lower doses used for insomnia, sedation is the intended effect rather than an adverse one.

Trazodone also carries a rare but serious risk of priapism, a prolonged and painful erection that is a urological emergency. Published incidence estimates vary across sources and were not independently confirmed for this draft; treat any specific ratio as needing verification, and counsel patients that priapism lasting more than a few hours requires emergency evaluation regardless of insurance coverage question. TRICARE emergency care benefits apply the same way to a priapism-related emergency department visit as to any other emergency.

Trazodone is metabolized through CYP3A4. Strong CYP3A4 inhibitors can raise trazodone blood levels, and the FDA label addresses dose adjustment in that setting. Combining trazodone with an MAOI is contraindicated because of serotonin syndrome risk. These interactions do not change TRICARE coverage, but they are exactly the kind of thing that can trigger an automated pharmacy edit and a temporary hold on a fill.

Anyone experiencing symptoms of serotonin syndrome (agitation, high fever, tremor, rapid heart rate) or a priapism episode should seek urgent or emergency care rather than waiting on a coverage or authorization question.

How to appeal a TRICARE trazodone denial

Denials for a low-cost generic drug like trazodone are uncommon, but they happen, often from a dose-limit edit, a duplicate-therapy flag, or an enrollment or eligibility issue. TRICARE's appeal structure generally follows three stages:

1. Reconsideration with the TRICARE regional contractor, using the Explanation of Benefits showing the denial plus a prescriber letter with clinical rationale.
2. Formal appeal to the same regional contractor, reviewed by a different clinical team, if reconsideration fails.
3. Independent external review, through the TRICARE Hearing Office (Prime) or an independent review organization (Select), producing a binding decision if the formal appeal fails.

Specific filing windows and decision timelines (how many days you have to file, how long a decision takes) are set administratively and can change; confirm the current numbers on your Explanation of Benefits or through the regional contractor rather than relying on a fixed day count from any secondary source, including this one. An expedited review pathway generally exists for urgent clinical situations, such as a patient in acute depressive crisis who tolerates only trazodone.

The strongest appeals typically combine a prescriber letter documenting treatment history and rationale, any relevant published clinical guidance, and documentation of prior treatment failure or intolerance with formulary alternatives.

Manufacturer savings cards and TRICARE

Federal law restricts the use of manufacturer copay cards and coupons with government-funded insurance programs, including TRICARE, under the Anti-Kickback Statute framework that HHS's Office of Inspector General has addressed in guidance on copay coupon programs (HHS). This is largely a moot point for trazodone specifically, since the original brand (Desyrel) has been discontinued and only generic versions are currently marketed, so there is no manufacturer coupon program to apply in the first place. The restriction is more relevant for beneficiaries on branded medications where a coupon could otherwise offset a meaningful copay.

Comparing trazodone to other TRICARE-covered options

SSRIs (sertraline, fluoxetine, escitalopram) are first-line for most depressive disorders under general psychiatric practice guidance, and trazodone is more often used as an adjunct for SSRI-related insomnia or as an alternative for patients who cannot tolerate an SSRI. Generic SSRIs and generic trazodone are both the type of drug that typically sits in a formulary's lowest-cost generic category.

Zolpidem is a Schedule IV controlled substance also commonly available as a low-cost generic; newer branded insomnia drugs such as suvorexant and lemborexant are more likely to carry a non-formulary or prior-authorization status because they are branded rather than generic. Trazodone's practical advantages in this comparison are that it is not scheduled, is inexpensive, and can address both mood and sleep symptoms in one prescription, though the strength of its insomnia evidence base is weaker than its depression evidence base.

Coverage and appeal decision framework

Use this sequence before assuming a denial, cost, or authorization requirement applies to your situation.

Step 1: Confirm the indication and dose you actually need.

• Standard depression dosing within the FDA label range → prior authorization is unlikely.
• Dose well above the standard outpatient range, or combined with another serotonergic drug → expect a possible automated edit; ask your prescriber to have justification ready before the pharmacy submits the claim.
• Off-label insomnia dosing (typically lower than the depression range) → coverage of the drug is not affected by the indication, but confirm the dose is within what your prescriber documents as clinically standard.

Step 2: Check your specific plan's cost-sharing rules before the fill.

• Military pharmacy, home delivery, and retail network pharmacies can have different copay structures. Use the TRICARE formulary search tool or call the pharmacy help line the same week you plan to fill, since published dollar figures age quickly.
• TRICARE For Life beneficiaries should check Medicare Part D coverage first, since Part D typically processes the claim before TRICARE For Life applies as secondary coverage.

Step 3: If the claim is rejected at the pharmacy, get the exact reject reason before calling anyone.

• Dose-limit edit → ask the prescriber to submit clinical justification directly to the regional contractor.
• Duplicate-therapy or interaction edit → ask the prescriber to confirm whether a genuine interaction risk exists (for example, another serotonergic drug or a strong CYP3A4 inhibitor) versus a false-positive edit.
• Eligibility or enrollment issue → resolve through DEERS or your regional contractor before resubmitting the pharmacy claim.

Step 4: If a formal denial follows, decide urgency before choosing a track.

• Routine, non-urgent situation → file reconsideration with the regional contractor first, in writing, with the Explanation of Benefits and a prescriber letter attached.
• Urgent clinical situation (for example, acute depressive crisis with trazodone as the only tolerated option) → ask the prescriber to explicitly request expedited review; do not wait for the standard reconsideration timeline.
• If reconsideration fails → escalate to the formal appeal, then to independent external review, adding any new clinical documentation at each stage.

Step 5: Do not let an insurance question delay emergency symptoms.

• Priapism lasting more than a few hours, or signs of serotonin syndrome, are medical emergencies. Seek emergency care first and resolve the coverage question afterward.